Biomarin Pharmaceutical Inc. (NASDAQ: BMRN)’s stock price has gone decline by -1.67 in comparison to its previous close of 82.13, however, the company has experienced a -12.27% decrease in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-25 that BioMarin’s (BMRN) earnings beat estimates in the first quarter of 2024, while revenues slightly miss the mark. The company maintains revenue guidance for 2024.
Is It Worth Investing in Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) Right Now?
Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) has a price-to-earnings ratio that is above its average at 75.58x. The stock has a 36-month beta value of 0.33. Opinions on the stock are mixed, with 12 analysts rating it as a “buy,” 7 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for BMRN is 186.03M, and at present, short sellers hold a 1.98% of that float. On May 01, 2024, the average trading volume of BMRN was 1.55M shares.
BMRN’s Market Performance
The stock of Biomarin Pharmaceutical Inc. (BMRN) has seen a -12.27% decrease in the past week, with a -7.28% drop in the past month, and a -9.89% fall in the past quarter. The volatility ratio for the week is 3.32%, and the volatility levels for the past 30 days are at 2.26% for BMRN. The simple moving average for the last 20 days is -8.59% for BMRN’s stock, with a simple moving average of -9.30% for the last 200 days.
Analysts’ Opinion of BMRN
Many brokerage firms have already submitted their reports for BMRN stocks, with Wells Fargo repeating the rating for BMRN by listing it as a “Overweight.” The predicted price for BMRN in the upcoming period, according to Wells Fargo is $100 based on the research report published on November 15, 2023 of the previous year 2023.
Bernstein, on the other hand, stated in their research note that they expect to see BMRN reach a price target of $82. The rating they have provided for BMRN stocks is “Mkt Perform” according to the report published on October 23rd, 2023.
BMRN Trading at -7.68% from the 50-Day Moving Average
After a stumble in the market that brought BMRN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.88% of loss for the given period.
Volatility was left at 2.26%, however, over the last 30 days, the volatility rate increased by 3.32%, as shares sank -6.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.02% lower at present.
During the last 5 trading sessions, BMRN fell by -12.27%, which changed the moving average for the period of 200-days by -5.95% in comparison to the 20-day moving average, which settled at $88.05. In addition, Biomarin Pharmaceutical Inc. saw -16.24% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BMRN starting from BIENAIME JEAN JACQUES, who sale 20,000 shares at the price of $91.26 back on Apr 12 ’24. After this action, BIENAIME JEAN JACQUES now owns 474,994 shares of Biomarin Pharmaceutical Inc., valued at $1,825,200 using the latest closing price.
BIENAIME JEAN JACQUES, the Director of Biomarin Pharmaceutical Inc., sale 20,000 shares at $90.99 during a trade that took place back on Apr 11 ’24, which means that BIENAIME JEAN JACQUES is holding 474,994 shares at $1,819,800 based on the most recent closing price.
Stock Fundamentals for BMRN
Current profitability levels for the company are sitting at:
- 0.07 for the present operating margin
- 0.77 for the gross margin
The net margin for Biomarin Pharmaceutical Inc. stands at 0.08. The total capital return value is set at 0.03. Equity return is now at value 4.22, with 3.09 for asset returns.
Based on Biomarin Pharmaceutical Inc. (BMRN), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at 0.26. The debt to equity ratio resting at 0.21. The interest coverage ratio of the stock is 10.23.
Currently, EBITDA for the company is 261.98 million with net debt to EBITDA at 1.21. When we switch over and look at the enterprise to sales, we see a ratio of 6.33. The receivables turnover for the company is 3.89for trailing twelve months and the total asset turnover is 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.74.
Conclusion
To sum up, Biomarin Pharmaceutical Inc. (BMRN) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
